Precision-Targeted Neoadjuvant CRIT Study Yields 51.1% Pathological Complete Response in Locally Advanced Rectal Cancer
Start here
At ESMO 2026, Professor Huang Jun presented the phase 2 CRIT study of biomarker-guided neoadjuvant therapy in high-risk pMMR/MSS locally advanced rectal cancer. All 49 enrolled patients had treatment selected according to RAS/BRAF status, receiving either cetuximab beta or bevacizumab. The overall pathological complete response (pCR) rate was 51.1%, with 57.1% in the RAS/BRAF wild-type subgroup and 46.2% in the mutant subgroup. Of the 47 patients who proceeded to surgery, 24 achieved pCR, and the R0 resection rate was 100%. The findings suggest molecularly tailored neoadjuvant regimens can produce high response rates in a population typically resistant to immunotherapy. Open questions include whether the results hold up in larger trials and what longer-term outcomes such as recurrence and organ preservation will show.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickESMO 2026: Professor Huang Jun Interprets the CRIT Precision-Targeted Neoadjuvant Study in Locally Advanced Rectal Cancer
At ESMO 2026, Professor Huang Jun presented the CRIT phase 2 study, in which 49 patients with high-risk pMMR/MSS locally advanced rectal cancer achieved an overall pathological complete response (pCR) rate of 51.1%. Treatment was selected by RAS/BRAF status, using cetuximab beta or bevacizumab; pCR rates were 57.1% in the wild-type subgroup and 46.2% in the mutant subgroup. Of 47 patients who underwent surgery, 24 achieved pCR, and the R0 resection rate was 100%.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.